By Natalie Huet PARIS (Reuters) - A new drug being developed by French drugmaker Sanofi and U.S. partner Regeneron cut "bad" LDL cholesterol more than placebo and existing treatments in nine late-stage clinical trials, the companies said on Wednesday. The injectable drug, called alirocumab, is from a promising new class of medicines, called PCSK9 inhibitors, also being developed by Amgen Inc and other drugmakers. The Phase III ODYSSEY trials showed that after 24 weeks, the mean percentage reduction in LDL cholesterol with alirocumab was consistent with results seen in previous trials, the companies said in a statement. The trials involved patients whose high LDL cholesterol levels are not sufficiently controlled by existing treatments such as statins, who cannot tolerate these or who present a high or very high cardiovascular risk.
via Health News Headlines - Yahoo News http://ift.tt/XepWee
No comments:
Post a Comment